Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …

Aims An algorithm for non‐invasive diagnosis of amyloid transthyretin cardiac amyloidosis
(ATTR‐CA) and novel disease‐modifying therapies have prompted an active search for CA …

The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …

Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly diagnosed owing to the
emergence of noninvasive imaging and improved awareness. Clinical penetrance of …

Background The impact of aortic valve replacement (AVR) on progression/regression of
extravalvular cardiac damage and its association with subsequent prognosis is unknown …

Systemic forms of amyloidosis affecting the heart are mostly light-chain (AL) and
transthyretin (ATTR) amyloidoses. The latter is caused by deposition of misfolded …

731 F. Beyersdorf and A. Vahanian et al./European Journal of Cardio-Thoracic Surgery
guidelines, which is freely available via the ESC and EACTS website and hosted on the EHJ …

Heart failure is a leading cause of mortality and hospitalization worldwide. Cardiac fibrosis,
resulting from the excessive deposition of collagen fibers, is a common feature across the …

Aim Systematic evidence on the prevalence and clinical outcome of transthyretin
amyloidosis (ATTR) is missing. We explored:(i) the prevalence of cardiac amyloidosis in …

Adverse cardiac remodelling is the main determinant of patient prognosis in degenerative
valvular heart disease (VHD). However, to give an indication for valvular intervention …